Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
Regorafenib is a multikinase inhibitor which showed benefits in pretreated metastatic colorectal cancer patients. Hepatotoxicity has been described as a frequent side effect. We report the case of a 65-year-old patient presenting with jaundice, fever, and hepatocellular insufficiency which led to de...
Main Authors: | Dominique Béchade, Marie Desjardin, Claire Castain, Pierre-Henri Bernard, Marianne Fonck |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-08-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/479732 |
Similar Items
-
Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01) -
The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01) -
The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01) -
Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01) -
Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)